JP2020500930A5 - - Google Patents

Download PDF

Info

Publication number: JP2020500930A5
Authority: JP; Japan
Prior art keywords: pharmaceutical composition; pharmaceutically acceptable; composition according; patient; bez235
Prior art date: 2017-11-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP2019547795A

Other languages

English (en)

Japanese (ja)

Other versions

JP2020500930A (ja

Filing date

2017-11-22

Publication date

2021-01-07

2017-11-22 Application filed filed Critical

2017-11-22 Priority claimed from PCT/IB2017/001579 external-priority patent/WO2018096402A1/en

2020-01-16 Publication of JP2020500930A publication Critical patent/JP2020500930A/ja

2021-01-07 Publication of JP2020500930A5 publication Critical patent/JP2020500930A5/ja

Status Pending legal-status Critical Current

Links

150000003839 salts Chemical class 0.000 claims description 48
238000000034 method Methods 0.000 claims description 38
JOGKUKXHTYWRGZ-UHFFFAOYSA-N dactolisib Chemical compound O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 JOGKUKXHTYWRGZ-UHFFFAOYSA-N 0.000 claims description 29
229950006418 dactolisib Drugs 0.000 claims description 29
201000010099 disease Diseases 0.000 claims description 11
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
206010057190 Respiratory tract infections Diseases 0.000 claims description 7
230000002159 abnormal effect Effects 0.000 claims description 5
108090000623 proteins and genes Proteins 0.000 claims description 5
102000014150 Interferons Human genes 0.000 claims description 3
108010050904 Interferons Proteins 0.000 claims description 3
230000001939 inductive effect Effects 0.000 claims description 3
229940079322 interferon Drugs 0.000 claims description 3
238000009097 single-agent therapy Methods 0.000 claims description 3
239000000427 antigen Substances 0.000 claims description 2
102000036639 antigens Human genes 0.000 claims description 2
108091007433 antigens Proteins 0.000 claims description 2
230000028993 immune response Effects 0.000 claims description 2
230000036039 immunity Effects 0.000 claims description 2
230000015788 innate immune response Effects 0.000 claims description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical class CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 claims description 2
239000008194 pharmaceutical composition Substances 0.000 claims 22
208000020029 respiratory tract infectious disease Diseases 0.000 claims 3
239000003814 drug Substances 0.000 claims 2
239000000203 mixture Substances 0.000 claims 2
206010062106 Respiratory tract infection viral Diseases 0.000 claims 1
208000020017 viral respiratory tract infection Diseases 0.000 claims 1
HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 14
229960005167 everolimus Drugs 0.000 description 14
208000015181 infectious disease Diseases 0.000 description 11
208000035473 Communicable disease Diseases 0.000 description 8
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 5
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 5
201000003793 Myelodysplastic syndrome Diseases 0.000 description 5
230000032683 aging Effects 0.000 description 5
210000002744 extracellular matrix Anatomy 0.000 description 5
238000007634 remodeling Methods 0.000 description 5
230000004064 dysfunction Effects 0.000 description 4
206010019280 Heart failures Diseases 0.000 description 3
208000019425 cirrhosis of liver Diseases 0.000 description 3
201000001320 Atherosclerosis Diseases 0.000 description 2
208000007342 Diabetic Nephropathies Diseases 0.000 description 2
201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
206010003246 arthritis Diseases 0.000 description 2
230000008499 blood brain barrier function Effects 0.000 description 2
210000001218 blood-brain barrier Anatomy 0.000 description 2
208000033679 diabetic kidney disease Diseases 0.000 description 2
208000036971 interstitial lung disease 2 Diseases 0.000 description 2
206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 2
201000008482 osteoarthritis Diseases 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
208000005069 pulmonary fibrosis Diseases 0.000 description 2
208000001076 sarcopenia Diseases 0.000 description 2
210000002435 tendon Anatomy 0.000 description 2
230000029663 wound healing Effects 0.000 description 2
206010058314 Dysplasia Diseases 0.000 description 1
206010019668 Hepatic fibrosis Diseases 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
208000020832 chronic kidney disease Diseases 0.000 description 1
208000022831 chronic renal failure syndrome Diseases 0.000 description 1
230000007882 cirrhosis Effects 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
208000028169 periodontal disease Diseases 0.000 description 1
230000009759 skin aging Effects 0.000 description 1
208000019206 urinary tract infection Diseases 0.000 description 1
230000003612 virological effect Effects 0.000 description 1

JP2019547795A 2016-11-23 2017-11-22 エベロリムス、ダクトリシブまたは両方で免疫応答を増強する方法 Pending JP2020500930A (ja)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US201662425766P	2016-11-23	2016-11-23
US62/425,766		2016-11-23
US201762476160P	2017-03-24	2017-03-24
US62/476,160		2017-03-24
US201762576511P	2017-10-24	2017-10-24
US62/576,511		2017-10-24
PCT/IB2017/001579 WO2018096402A1 (en)	2016-11-23	2017-11-22	Methods of enhancing immune response with everolimus, dactolisib or both

Publications (2)

Publication Number	Publication Date
JP2020500930A JP2020500930A (ja)	2020-01-16
JP2020500930A5 true JP2020500930A5 (2)	2021-01-07

Family

ID=60957348

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2019547795A Pending JP2020500930A (ja)	2016-11-23	2017-11-22	エベロリムス、ダクトリシブまたは両方で免疫応答を増強する方法

Country Status (12)

Country	Link
US (3)	US10441584B2 (2)
EP (1)	EP3544608A1 (2)
JP (1)	JP2020500930A (2)
KR (1)	KR20190089005A (2)
CN (1)	CN110114070A (2)
AU (1)	AU2017363970A1 (2)
BR (1)	BR112019010470A2 (2)
CA (1)	CA3044355A1 (2)
IL (1)	IL266750A (2)
MX (1)	MX2019006090A (2)
TW (1)	TW201825090A (2)
WO (1)	WO2018096402A1 (2)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11083725B2 (en)	2014-10-24	2021-08-10	St. Jude Children's Research Hospital	Coordinated metabolic reprogramming in response to productive viral infections
CN110114070A (zh)	2016-11-23	2019-08-09	诺华公司	使用依维莫司(everolimus)、达托里昔布(dactolisib)或二者增强免疫反应的方法
US10596165B2 (en)	2018-02-12	2020-03-24	resTORbio, Inc.	Combination therapies
WO2020223154A1 (en) *	2019-05-01	2020-11-05	resTORbio, Inc.	Methods of enhancing immune response

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1028606A (en)		1912-06-04	Victor Talking Machine Co	Sound-box for talking-machines.
US1000480A (en)	1909-05-19	1911-08-15	J G Brill Co	Car-truck.
US1044158A (en)	1911-01-27	1912-11-12	Allen H Fetzer	Trolley-wheel.
ZA737247B (en)	1972-09-29	1975-04-30	Ayerst Mckenna & Harrison	Rapamycin and process of preparation
US5472712A (en)	1991-12-24	1995-12-05	Euroceltique, S.A.	Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5681585A (en)	1991-12-24	1997-10-28	Euro-Celtique, S.A.	Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
GB9221220D0 (en)	1992-10-09	1992-11-25	Sandoz Ag	Organic componds
CA2175215C (en)	1993-11-19	2008-06-03	Yat Sun Or	Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
SK78196A3 (en)	1993-12-17	1997-02-05	Sandoz Ag	Rapamycin demethoxy-derivatives, preparation method thereof and pharmaceutical agent containing them
US5362718A (en)	1994-04-18	1994-11-08	American Home Products Corporation	Rapamycin hydroxyesters
US5741677A (en)	1995-06-07	1998-04-21	Geron Corporation	Methods for measuring telomere length
US5985890A (en)	1995-06-09	1999-11-16	Novartis Ag	Rapamycin derivatives
FR2736550B1 (fr)	1995-07-14	1998-07-24	Sandoz Sa	Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
AU735648B2 (en)	1996-07-12	2001-07-12	Ariad Pharmaceuticals, Inc.	Materials and method for treating or preventing pathogenic fungal infection
CA2230748C (en)	1997-03-14	2010-08-03	American Home Products Corporation	Rapamycin formulations for oral administration
US6015815A (en)	1997-09-26	2000-01-18	Abbott Laboratories	Tetrazole-containing rapamycin analogs with shortened half-lives
TW557297B (en)	1997-09-26	2003-10-11	Abbott Lab	Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
ME00189B (me)	1998-03-26	2011-02-10	Astellas Pharma Inc	Preparati sa neprekidnim oslobađanjem
ATE264863T1 (de)	1999-08-24	2004-05-15	Ariad Gene Therapeutics Inc	28-epirapaloge
GB0008785D0 (en)	2000-04-10	2000-05-31	Novartis Ag	Organic compounds
GB0123400D0 (en)	2001-09-28	2001-11-21	Novartis Ag	Organic compounds
PT1478648E (pt)	2002-02-01	2014-07-15	Ariad Pharma Inc	Compostos contendo fósforo e suas utilizações
US20030203027A1 (en)	2002-04-26	2003-10-30	Ethicon, Inc.	Coating technique for deposition of drug substance on a substrate
US7075204B2 (en)	2003-08-06	2006-07-11	Honeywell International, Inc.	Threaded inner sleeve for generator magnet
AR045957A1 (es)	2003-10-03	2005-11-16	Novartis Ag	Composicion farmaceutica y combinacion
US7220755B2 (en)	2003-11-12	2007-05-22	Biosensors International Group, Ltd.	42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
GB0419355D0 (en)	2004-08-31	2004-09-29	Novartis Ag	Organic compounds
US8758816B2 (en)	2004-11-24	2014-06-24	Meda Pharmaceuticals Inc.	Compositions comprising azelastine and methods of use thereof
DK1848431T3 (en)	2005-02-09	2016-04-18	Santen Pharmaceutical Co Ltd	LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS
BRPI0608573A2 (pt)	2005-03-08	2017-07-25	Lifecycle Pharma As	Composição farmacêutica, e, método para a preparação de uma composição farmacêutica.
GB0510390D0 (en)	2005-05-20	2005-06-29	Novartis Ag	Organic compounds
ES2563288T3 (es)	2006-03-23	2016-03-14	Santen Pharmaceutical Co., Ltd	Rapamicina en dosis bajas para el tratamiento de enfermedades relacionadas con la permeabilidad vascular
US20100266590A1 (en)	2006-08-02	2010-10-21	Demetri George D	Combination therapy
EP1902708A1 (de)	2006-09-25	2008-03-26	Losan Pharma GmbH	Wirkstoff enthaltende stabilisierte feste Arzneimittelformen und Verfahren zu ihrer Herstellung
KR20140091718A (ko)	2006-11-20	2014-07-22	노파르티스 아게	2-메틸-2-［4-(3-메틸-2-옥소-8-퀴놀린-3-일-2,3-디히드로-이미다조［4,5-ｃ］퀴놀린-1-일)-페닐］-프로피오니트릴의 염 및 결정 형태
AU2008218806B2 (en)	2007-02-20	2011-12-01	Novartis Ag	Imidazoquinolines as dual lipid kinase and mTOR inhibitors
PL2182948T3 (pl)	2007-07-24	2013-07-31	Novartis Ag	Zastosowanie imidazochinolin do leczenia chorób EGFR-zależnych albo chorób wykazujących nabytą oporność wobec środków ukierunkowanych na członków rodziny EGFR
US20090082387A1 (en)	2007-09-26	2009-03-26	Protia, Llc	Deuterium-enriched nvp-bez234
US20090088373A1 (en)	2007-09-28	2009-04-02	Gallo Richard L	Use of compositions to enhance innate immune response
JP2011513391A (ja)	2008-03-05	2011-04-28	パナセアバイオテックリミテッド	ミコフェノラートを含有する徐放性医薬組成物およびその方法
KR20100126553A (ko)	2008-03-26	2010-12-01	노파르티스 아게	Ｖｅｇｆ-유도성 혈관신생 과정의 유력한 조절제로서의 이미다조퀴놀린 및 피리미딘 유도체
CA2733203A1 (en)	2008-08-05	2010-02-11	Emory University	Use of mtor inhibitors to enhance t cell immune responses
EP2331566B1 (en)	2008-08-26	2015-10-07	City of Hope	Method and compositions for enhanced anti-tumor effector functioning of t cells
WO2010049481A1 (en)	2008-10-31	2010-05-06	Novartis Ag	Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor
ES2645692T3 (es)	2008-11-11	2017-12-07	The Board Of Regents,The University Of Texas System	Microcápsulas de rapamicina y su uso para el tratamiento del cáncer
US8323649B2 (en)	2008-11-25	2012-12-04	Alderbio Holdings Llc	Antibodies to IL-6 and use thereof
US9452227B2 (en)	2008-11-25	2016-09-27	Alderbio Holdings Llc	Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
EP2375897A4 (en)	2009-01-14	2013-05-15	Health Research Inc	METHOD AND COMPOSITIONS USING MTOR-INHIBITORS FOR IMPROVING IMMUNE REACTIONS
US20100233733A1 (en)	2009-02-10	2010-09-16	Nodality, Inc., A Delaware Corporation	Multiple mechanisms for modulation of the pi3 kinase pathway
CA2757979A1 (en)	2009-04-09	2010-10-14	Alkermes Pharma Ireland Limited	Controlled-release clozapine compositions
BRPI1010655A2 (pt)	2009-04-10	2019-09-03	Qi Haiyan	novos agentes antienvelhecimento e métodos para identificá-los
CN101862297B (zh)	2009-04-14	2012-07-25	上海医药工业研究院	一种非水溶性药物的缓释微丸、其缓释口腔崩解片及其制备方法
US20120114637A1 (en)	2009-05-04	2012-05-10	Santen Pharmaceutical Co., Ltd.	Mtor pathway inhibitors for treating ocular disorders
JP2013504325A (ja)	2009-09-09	2013-02-07	アビラセラピューティクス，インコーポレイテッド	Ｐｉ３キナーゼインヒビターおよびその使用
CN102199152A (zh)	2010-03-25	2011-09-28	高大新	杂环咪唑类磷脂激酶抑制剂
US20130296316A1 (en)	2010-07-09	2013-11-07	Michael P. Pollastri	Antiparasitic Agents Based On mTOR Inhibitors
AR083267A1 (es)	2010-10-04	2013-02-13	Novartis Ag	Combinaciones farmaceuticas
WO2012075253A2 (en)	2010-12-03	2012-06-07	Novartis Ag	Pharmaceutical compositions
PH12013501201A1 (en)	2010-12-09	2013-07-29	Univ Pennsylvania	Use of chimeric antigen receptor-modified t cells to treat cancer
EP2667874A4 (en)	2011-01-27	2014-07-30	Univ Princeton	MTOR KINASE HEMMER AS ANTIVIRUS AGENT
CN103391780B (zh) *	2011-02-16	2015-08-19	诺瓦提斯公司	用于治疗神经变性疾病的治疗剂的组合物
CN102138903B (zh)	2011-03-17	2012-12-12	苏州特瑞药业有限公司	一种依维莫司固体口服药物组合物
EP2741747A1 (en)	2011-08-10	2014-06-18	Novartis Pharma AG	JAK P13K/mTOR COMBINATION THERAPY
MX2014003873A (es)	2011-09-30	2014-05-28	Dana Farber Cancer Inst Inc	Metodo para tratar el carcinoma mucoepidermoide.
ES2663744T3 (es)	2011-10-06	2018-04-16	Novartis Ag	Composiciones farmacéuticas que comprenden 40-O-(2-hidroxi)etil-rapamicina
EP2638896A1 (en)	2012-03-14	2013-09-18	Bioneer A/S	Cationic liposomal drug delivery system for specific targeting of human cd14+ monocytes in whole blood
RU2766608C2 (ru)	2012-04-11	2022-03-15	Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез	Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток
RU2014154009A (ru)	2012-06-06	2016-08-10	Новартис Аг	Комбинация ингибитора 17-альфа-гидроксилазы (с17,20-лиазы) и специфического ингибитора pi-3k для лечения онкологического заболевания
US10799473B2 (en)	2013-03-04	2020-10-13	The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.	Methods of inhibiting IGF-1R activation or downtream signalling thereof to reduce radiation-induced cellular senescence
TW201503912A (zh)	2013-03-19	2015-02-01	Novartis Ag	包含癌莫事（ｅｖｅｒｏｌｉｍｕｓ）之醫藥組合物
WO2014191128A1 (en)	2013-05-29	2014-12-04	Cellectis	Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
KR101582264B1 (ko)	2013-06-27	2016-01-04	삼성전자 주식회사	유기 박막용 조성물, 유기 박막 및 상기 유기 박막을 포함하는 전자 소자
US9033062B2 (en) *	2013-07-11	2015-05-19	Caterpillar Inc.	Control system for a machine
AU2014348657A1 (en)	2013-11-13	2016-05-19	Novartis Ag	mTOR inhibitors for enhancing the immune response
SI3151672T1 (sl)	2014-06-06	2021-03-31	Bluebird Bio, Inc.	Izboljšani T-celični sestavki
SG10201913782UA (en)	2014-07-21	2020-03-30	Novartis Ag	Treatment of cancer using a cll-1 chimeric antigen receptor
US20170274014A1 (en)	2014-07-21	2017-09-28	Jennifer Brogdon	Combinations of low, immune enhancing, doses of mtor inhibitors and cars
TWI719942B (zh)	2014-07-21	2021-03-01	瑞士商諾華公司	使用ｃｄ３３嵌合抗原受體治療癌症
BR112017001183A2 (pt)	2014-07-21	2017-11-28	Novartis Ag	tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
JP2017528433A (ja)	2014-07-21	2017-09-28	ノバルティスアーゲー	低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
MX2017002205A (es)	2014-08-19	2017-08-21	Novartis Ag	Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer.
US11083725B2 (en) *	2014-10-24	2021-08-10	St. Jude Children's Research Hospital	Coordinated metabolic reprogramming in response to productive viral infections
WO2016079332A1 (en)	2014-11-21	2016-05-26	Technical University Of Denmark	Gel formulations for improving immunotherapy
CA2986359A1 (en)	2015-05-20	2016-11-24	Novartis Ag	Pharmaceutical combination of everolimus with dactolisib
CN110114070A (zh)	2016-11-23	2019-08-09	诺华公司	使用依维莫司(everolimus)、达托里昔布(dactolisib)或二者增强免疫反应的方法

2017
- 2017-11-22 CN CN201780080148.2A patent/CN110114070A/zh active Pending
- 2017-11-22 EP EP17829013.6A patent/EP3544608A1/en not_active Withdrawn
- 2017-11-22 CA CA3044355A patent/CA3044355A1/en not_active Abandoned
- 2017-11-22 TW TW106140519A patent/TW201825090A/zh unknown
- 2017-11-22 MX MX2019006090A patent/MX2019006090A/es unknown
- 2017-11-22 WO PCT/IB2017/001579 patent/WO2018096402A1/en not_active Ceased
- 2017-11-22 US US15/821,229 patent/US10441584B2/en active Active
- 2017-11-22 BR BR112019010470A patent/BR112019010470A2/pt not_active Application Discontinuation
- 2017-11-22 JP JP2019547795A patent/JP2020500930A/ja active Pending
- 2017-11-22 KR KR1020197017560A patent/KR20190089005A/ko not_active Withdrawn
- 2017-11-22 AU AU2017363970A patent/AU2017363970A1/en not_active Abandoned
2019
- 2019-05-20 IL IL266750A patent/IL266750A/en unknown
- 2019-10-03 US US16/592,248 patent/US11045463B2/en active Active
- 2019-10-03 US US16/592,293 patent/US10993940B2/en active Active

Publication	Publication Date	Title
JP2015517489A5 (2)	2016-06-30
JP2014528474A5 (2)	2015-11-12
JP2020500930A5 (2)	2021-01-07
JP2016074740A5 (2)	2016-08-18
CA2923685A1 (en)	2015-03-19	Application of r-ketamine and salt thereof as pharmaceuticals
JP2014528901A5 (2)	2015-04-30
JP2016501865A5 (2)	2017-01-12
JP2015522630A5 (2)	2016-06-23
JP2016531144A5 (2)	2018-04-05
JP2015517488A5 (2)	2016-06-30
KR20190073365A (ko)	2019-06-26	사이토카인 과분비 및 바이러스성 감염의 치료를 위한 비만 세포 안정화제
JP2011225596A5 (2)	2012-04-05
JP2016525548A5 (2)	2017-08-31
JP2014198723A5 (2)	2015-02-26
JP2017501140A5 (2)	2018-01-25
JP2013518124A5 (2)	2014-03-20
RU2014141893A (ru)	2016-05-10	Применение производной пиразола в лечении острых приступов хронической обструктивной болезни легких
JP2016507500A5 (2)	2017-02-09
JP2017533211A5 (2)	2018-12-13
JP2011500776A5 (2)	2011-10-06
JP2020536121A5 (2)	2021-12-02
JP2019507786A5 (2)	2019-05-09
JP2016515137A5 (2)	2017-04-20
JP2013536206A5 (2)	2014-10-09
IL272834B2 (en)	2024-08-01	Amantadine compositions, preparations thereof, and methods of use